Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL

Last Updated: Wednesday, November 1, 2023

Patients with CLL tend to have an impaired immune response to vaccination, with slower and lower anti-spike protein antibody levels in response to immunizations. However, decreased mortality and hospitalization rates may be associated with additional COVID-19 vaccine doses which can boost detectable anti-spike protein levels (≥ 5,000 AU/mL).

British Journal of Hematology

Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL

Hematological Oncology

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

Blood Advances

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

2023 Meeting of the Society of Hematologic Oncology (SOHO)

Outcomes of U.S. military veterans with chronic lymphocytic leukemia (CLL) treated with different first-line treatments from 1998 to 2020.

American Journal of Hematology

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center single-arm, open-label, phase 2 study

FDA.gov

FDA approves zanubrutinib for CLL or SLL

Blood

Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study

European Hematology Association 2022 Congress Abstract

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study

Blood

Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease

Blood

Genetic markers and front line FCR/BR vs. RVe, GVe and GIVe treatment: Outcome results from the CLL13/GAIA trial

Chronic Lymphocytic Leukemia Resource Center

Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL

British Journal of Hematology

Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL

Hematological Oncology

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

Blood Advances

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

2023 Meeting of the Society of Hematologic Oncology (SOHO)

Outcomes of U.S. military veterans with chronic lymphocytic leukemia (CLL) treated with different first-line treatments from 1998 to 2020.

American Journal of Hematology

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center single-arm, open-label, phase 2 study

FDA.gov

FDA approves zanubrutinib for CLL or SLL

Blood

Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study

European Hematology Association 2022 Congress Abstract

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study

Blood

Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease

Blood

Genetic markers and front line FCR/BR vs. RVe, GVe and GIVe treatment: Outcome results from the CLL13/GAIA trial

“Double-Refractory” CLL: Progressive Disease after Therapy With Both a BTK Inhibitor and a BCL2 Inhibitor

Management of Atrial Fibrillation in Patients With CLL on BTK Inhibitors

The Importance of Shared Decision-Making in the Frontline Setting